Ask AI
ProCE Banner Activity

Expanded Q&A From HBV Live! A Deep Dive Into the Evolving Landscape of Hepatitis B Management

Clinical Thought

In this commentary, a panel of expert healthcare professionals answers audience questions from a symposium on the prevention and management of hepatitis B infection.

Released: May 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This educational activity is supported by an independent medical education grant from GSK.

GSK

Target Audience

This activity is intended for physicians, including gastroenterologists and hepatologists, nurse practitioners, physician associates, and other healthcare professionals involved in the care of people living with chronic hepatitis B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate current evidence-based treatment and monitoring strategies into the clinical management of patients with chronic hepatitis B

  • Compare the benefits of functional cure vs lifelong antiviral suppression for patients with chronic hepatitis B

  • Outline the potential role of investigational therapies targeting functional cure for HBV

Disclosure

Primary Author

Jordan J. Feld, MD, MPH: consultant/advisor/speaker: AbbVie, Aligos, Arbutus, AstraZeneca, AusperBio, Gilead, Vir; researcher: Gilead, GSK, Vir.

Mark Sulkowski, MD, FAASLD: consultant/advisor: AbbVie, Aligos, AstraZeneca, Bluejay, GSK, Precision Biosciences, Vir, Virion; researcher (paid to institution): Aligos, Bluejay, GSK, Griffols, Vir.

Norah Terrault, MD, MPH: consultant/advisor/speaker: Bluejay, GSK; researcher: Aligos, Bluejay, Durect, GSK, ImmunoCore, Vir Biotech.